BA
PRQR icon

BlackRock Advisors’s ProQR Therapeutics PRQR Stock Holding History

BlackRock Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-60,600
Closed -$1.31M – 3651
2014
Q4 		$1.31M Sell
60,600
-200
-0.3% -$3.04K ﹤0.01% 1354
2014
Q3 		$1.04M Buy
+60,800
New +$974K ﹤0.01% 1409

Other funds holding PRQR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock Advisors's PRQR Position: Q1 2015 in Review

BlackRock Advisors sold out of ProQR Therapeutics (PRQR) in Q1 2015, closing a stake of 60,600 shares — an estimated $1.31M sold.

BlackRock Advisors first reported a position in PRQR in Q3 2014 and held it in 2 quarters. The position peaked at $1.31M in Q4 2014. 38 funds tracked by Wall St. Rank hold PRQR as of Q1 2015.

  • BlackRock Advisors reported no remaining ProQR Therapeutics position as of Q1 2015 after selling out during the quarter.
  • BlackRock Advisors sold 60,600 ProQR Therapeutics shares in Q1 2015, an estimated $1.31M.
  • BlackRock Advisors first reported a position in ProQR Therapeutics in Q3 2014 and held it in 2 quarters.
  • BlackRock Advisors's ProQR Therapeutics position peaked at $1.31M in Q4 2014.
  • 38 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2015.

Based on BlackRock Advisors's 13F filing for Q1 2015, filed 13 May 2015.